ArticleAnnals of pediatric cardiology
ThoroughFare atrial pressure controller device to create a controlled interatrial right-to-left shunt in advanced pulmonary arterial hypertension - A pilot study.
Article in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial flow regulators are used in patients with pulmonary arterial hypertension (PAH) who present with syncope or advanced heart failure. The ThoroughFare atrial pressure controller (Meril Life Sciences, Vapi, India) is a new device for similar use. The differences in structural design include a cable-screw release mechanism and a low profile. Methods: A multi-institutional study assessed the feasibility and safety of this device and reported short-term follow-up. This device, with an 8-mm fenestration diameter, was deployed after transseptal puncture using a 12F sheath. Results: Between April 2023 and June 2024, 15 symptomatic patients aged 5-39 years, including four children, received this implant after dual pulmonary vasodilator pharmacotherapy for at least 2 years. Etiology included idiopathic PAH in eight patients, hereditary PAH in two, operated shunt lesions in four, and human immunodeficiency virus-associated PAH in one patient. The key indication was recurrent syncope in 11 and right heart failure in the rest. The mean N-terminal pro-brain natriuretic peptide was 2414 ± 2046 pg/mL. The hemodynamic assessment revealed high right atrial pressures in 80% of patients, low cardiac index in half, and suprasystemic pulmonary pressures in four patients. The procedure was completed in all patients without any complications. Pulse oximeter saturations dropped from 98% ±2% to 92% ±4%. Symptoms improved over a median follow-up of 8 months, and the device patency was confirmed in all patients except one patient who died 5 months postprocedure after a heart-lung transplantation. Conclusion: ThoroughFare atrial pressure controller implantation was feasible and safe for all patients with severe PAH without any complications. Longer follow-up with more patients is needed to ascertain the functional improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.